BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 26949218)

  • 1. Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.
    Scott-McKean JJ; Surewicz K; Choi JK; Ruffin VA; Salameh AI; Nieznanski K; Costa ACS; Surewicz WK
    Neurobiol Dis; 2016 Jul; 91():124-131. PubMed ID: 26949218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers.
    Laurén J; Gimbel DA; Nygaard HB; Gilbert JW; Strittmatter SM
    Nature; 2009 Feb; 457(7233):1128-32. PubMed ID: 19242475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice.
    Rammes G; Gravius A; Ruitenberg M; Wegener N; Chambon C; Sroka-Saidi K; Jeggo R; Staniaszek L; Spanswick D; O'Hare E; Palmer P; Kim EM; Bywalez W; Egger V; Parsons CG
    Neuropharmacology; 2015 May; 92():170-82. PubMed ID: 25637092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices.
    Rammes G; Hasenjäger A; Sroka-Saidi K; Deussing JM; Parsons CG
    Neuropharmacology; 2011 May; 60(6):982-90. PubMed ID: 21310164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Prion Protein Binds Isolated Low Molecular Weight Amyloid-β Oligomers Causing Cytotoxicity Inhibition.
    Williams TL; Choi JK; Surewicz K; Surewicz WK
    ACS Chem Neurosci; 2015 Dec; 6(12):1972-80. PubMed ID: 26466138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits.
    Izzo NJ; Staniszewski A; To L; Fa M; Teich AF; Saeed F; Wostein H; Walko T; Vaswani A; Wardius M; Syed Z; Ravenscroft J; Mozzoni K; Silky C; Rehak C; Yurko R; Finn P; Look G; Rishton G; Safferstein H; Miller M; Johanson C; Stopa E; Windisch M; Hutter-Paier B; Shamloo M; Arancio O; LeVine H; Catalano SM
    PLoS One; 2014; 9(11):e111898. PubMed ID: 25390368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective Effects of Ferruginol, Jatrophone, and Junicedric Acid Against Amyloid-β Injury in Hippocampal Neurons.
    Zolezzi JM; Lindsay CB; Serrano FG; Ureta RC; Theoduloz C; Schmeda-Hirschmann G; Inestrosa NC
    J Alzheimers Dis; 2018; 63(2):705-723. PubMed ID: 29660932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease.
    Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ
    Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein.
    Barry AE; Klyubin I; Mc Donald JM; Mably AJ; Farrell MA; Scott M; Walsh DM; Rowan MJ
    J Neurosci; 2011 May; 31(20):7259-63. PubMed ID: 21593310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dextran sulfate sodium inhibits amyloid-β oligomer binding to cellular prion protein.
    Aimi T; Suzuki K; Hoshino T; Mizushima T
    J Neurochem; 2015 Aug; 134(4):611-7. PubMed ID: 25963375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau
    Ondrejcak T; Klyubin I; Corbett GT; Fraser G; Hong W; Mably AJ; Gardener M; Hammersley J; Perkinton MS; Billinton A; Walsh DM; Rowan MJ
    J Neurosci; 2018 Dec; 38(50):10595-10606. PubMed ID: 30355631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein.
    Balducci C; Beeg M; Stravalaci M; Bastone A; Sclip A; Biasini E; Tapella L; Colombo L; Manzoni C; Borsello T; Chiesa R; Gobbi M; Salmona M; Forloni G
    Proc Natl Acad Sci U S A; 2010 Feb; 107(5):2295-300. PubMed ID: 20133875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
    Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W
    Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity.
    Izzo NJ; Xu J; Zeng C; Kirk MJ; Mozzoni K; Silky C; Rehak C; Yurko R; Look G; Rishton G; Safferstein H; Cruchaga C; Goate A; Cahill MA; Arancio O; Mach RH; Craven R; Head E; LeVine H; Spires-Jones TL; Catalano SM
    PLoS One; 2014; 9(11):e111899. PubMed ID: 25390692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal cellular prion protein drives fibrillization of amyloid beta and counteracts amyloid beta-mediated neurotoxicity.
    Falker C; Hartmann A; Guett I; Dohler F; Altmeppen H; Betzel C; Schubert R; Thurm D; Wegwitz F; Joshi P; Verderio C; Krasemann S; Glatzel M
    J Neurochem; 2016 Apr; 137(1):88-100. PubMed ID: 26710111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astrocytic glutamatergic transporters are involved in Aβ-induced synaptic dysfunction.
    Huang S; Tong H; Lei M; Zhou M; Guo W; Li G; Tang X; Li Z; Mo M; Zhang X; Chen X; Cen L; Wei L; Xiao Y; Li K; Huang Q; Yang X; Liu W; Zhang L; Qu S; Li S; Xu P
    Brain Res; 2018 Jan; 1678():129-137. PubMed ID: 29066369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Small Molecule GAL-201 Efficiently Detoxifies Soluble Amyloid β Oligomers: New Approach towards Oral Disease-Modifying Treatment of Alzheimer's Disease.
    Russ H; Mazzanti M; Parsons C; Riemann K; Gebauer A; Rammes G
    Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy.
    Nieznanska H; Bandyszewska M; Surewicz K; Zajkowski T; Surewicz WK; Nieznanski K
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt A):2143-2153. PubMed ID: 29604335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-prion RNA aptamer R12 disrupts the Alzheimer's disease-related complex between prion and amyloid β.
    Iida M; Mashima T; Yamaoki Y; So M; Nagata T; Katahira M
    FEBS J; 2019 Jun; 286(12):2355-2365. PubMed ID: 30916478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.
    Mengel D; Hong W; Corbett GT; Liu W; DeSousa A; Solforosi L; Fang C; Frosch MP; Collinge J; Harris DA; Walsh DM
    Brain Res; 2019 May; 1710():125-135. PubMed ID: 30593771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.